TY  - GEN
AU  - Baird,Richard D
AU  - van Rossum,Annelot G J
AU  - Oliveira,Mafalda
AU  - Beelen,Karin
AU  - Gao,Meiling
AU  - Schrier,Mariette
AU  - Mandjes,Ingrid A M
AU  - Garcia-Corbacho,Javier
AU  - Vallier,Anne-Laure
AU  - Dougall,Greig
AU  - van Werkhoven,Erik
AU  - Linossi,Constanza
AU  - Kumar,Sanjeev
AU  - van Tinteren,Harm
AU  - Callari,Maurizio
AU  - Beddowes,Emma
AU  - Perez-Garcia,José-Manuel
AU  - Rosing,Hilde
AU  - Platte,Else
AU  - Nederlof,Petra
AU  - Schot,Margaret
AU  - de Vries Schultink,Aurelia
AU  - Bernards,René
AU  - Saura,Cristina
AU  - Gallagher,William
AU  - Cortès,Javier
AU  - Caldas,Carlos
AU  - Linn,Sabine C
TI  - POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
SN  - 1557-3265
PY  - 2020///0910
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - diagnosis
KW  - Circulating Tumor DNA
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - administration & dosage
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - Neoplasm Staging
KW  - Oxazepines
KW  - Receptors, Estrogen
KW  - genetics
KW  - Receptors, Progesterone
KW  - Retreatment
KW  - Tamoxifen
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-19-0508
ER  -